Epitel

Executive Summary

Epitel is a digital health company revolutionizing brain health monitoring with its REMI Remote EEG Monitoring System. The wireless, wearable EEG platform addresses a critical need for continuous, real-time seizure detection in both hospital and home settings. By leveraging proprietary sensor technology and AI-driven analytics, Epitel aims to improve patient outcomes and reduce healthcare costs associated with epilepsy and other neurological conditions. Founded in 2016 and headquartered in Salt Lake City, Utah, the company operates in the neuroscience, medical devices, and digital health sectors. Epitel's competitive advantage lies in its ability to provide high-quality EEG data remotely, enabling timely interventions and better management of neurological disorders. The platform's AI algorithms enhance seizure detection accuracy, potentially outperforming traditional monitoring methods. As the demand for remote patient monitoring grows, Epitel is well-positioned to capture market share. However, as a private company with no disclosed funding or revenue, its trajectory depends on successful regulatory clearances and commercial adoption. If Epitel can secure FDA approvals and forge strategic partnerships, it could become a leader in remote neurological monitoring.

Upcoming Catalysts (preview)

• TBDFDA 510(k) Clearance for Expanded Indication70% success
• TBDKey Clinical Data Publication60% success
• TBDStrategic Partnership with Healthcare System50% success